Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Alfaro

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Revista Clinica Espanola|July 8, 2019
Hip fracture co-management in the elderly in a tertiary referral hospital: A cohorts studyM Rincón Gómez, C Hernández Quiles, M García Gutiérrez, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 27, 2001
Quantification of optic nerve axon loss associated with a relative afferent pupillary defect in the monkeyJ B Kerrison, K Buchanan, M L Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2011
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaA Gronchi, B N Bui, S Bonvalot, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Revista Clinica Espanola|July 8, 2019
Hip fracture co-management in the elderly in a tertiary referral hospital: A cohorts studyM Rincón Gómez, C Hernández Quiles, M García Gutiérrez, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 27, 2001
Quantification of optic nerve axon loss associated with a relative afferent pupillary defect in the monkeyJ B Kerrison, K Buchanan, M L Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialA Poveda, I Vergote, S Tjulandin, et al.
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2011
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaA Gronchi, B N Bui, S Bonvalot, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Pageof 7